| Antwerp radiotherapy centre chooses TomoTherapy cancer treatment ...
Madison, Wis., USA. The new University Radiotherapy Centre of Antwerp has chosen the TomoTherapy HiArt treatment system for providing radiation therapy, and the Centre will serve as a European training facility for TomoTherapy Incorporated (NASDAQ: TTPY). Hospitals participating in the Centre include University Hospital Antwerp and the Antwerp City Hospital Network. Two HiArt treatment systems have been installed on-site at University Hospital Antwerp. Through the University Radiotherapy Center, both member hospitals will use HiArt treatment systems to treat cancer patients with advanced image-guided, intensity-modulated radiation therapy (IG/IMRT). And, through collaboration with TomoTherapy, the machines will also be available for training physicians, hospital staff and TomoTherapy employees while still providing uninterrupted patient care.
North American Scientific Wins Renewal of Premier Contract to Sell ...
CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq:NASI) today announced the renewal by Premier Inc. of a new three year contract to supply its member hospitals with Prospera® I-125 and Pd-103 brachytherapy sources. Premier Inc. is one of the largest healthcare group purchasing organizations in the United States. The new three-year contract, which will become effective on August 1, 2007, will be implemented seamlessly upon the expiration of the current contract. "We are proud that Premier has chosen to renew our brachytherapy seed contract and we look forward to continuing our service to their member hospitals," stated John Rush, President and Chief Executive Officer of North American Scientific, Inc. "The renewal of the Premier contract marks another important milestone in the continued market acceptance of the Prospera® brand in the brachytherapy market, and we look forward to strengthening our collaboration with Premier as we work together in the battle against prostate cancer." About North American Scientific North American Scientific is a leader in radiation therapy products and services in the fight against cancer.
Use of Marker To Predict How Pancreatic Cancer Patients Do After ...
Researchers has found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation. The levels of the protein CA 19-9 in the blood can be used to determine the need for further therapy, they say.Adam Berger, M.D., assistant professor of surgery at Jefferson Medical College of Thomas Jefferson University, and his co-workers examined CA 19-9 levels and the survival of 385 patients with advanced pancreatic cancer who were treated with surgery and subsequent chemotherapy and radiation. They found that those patients whose post-operative CA 19-9 level exceeded 180 U/ml did much worse than those with lower levels.In fact, at least half of those whose CA 19-9 level was higher than 180 U/ml lived for approximately nine months, while half of those whose levels were 180 or below lived more than twice as long, about 21 months.
|
